https://doi.org/10.4081/monaldi.2022.2022
Role of IP-10 during follow up of pulmonary tuberculosis patients
Submitted: July 20, 2021
Accepted: December 21, 2021
Published: January 27, 2022
Accepted: December 21, 2021
Abstract Views: 1304
PDF: 640
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Pulmonary tuberculosis (PTB) is an infectious disease caused by Mycobacterium tuberculosis (MTB) and is associated with significant mortality and morbidity. There has been a number of advances in the diagnosis of PTB but there is a need for simple blood based diagnostic test. A follow up of the patients on treatment remains challenging. This study was planned to evaluate the role of IP-10 in the follow up of PTB patients. A total of 60 subjects were enrolled in the study, 40 patients with confirmed diagnosis of PTB and 20 healthy controls. The value of interferon (IFN)γ inducible protein 10 (IP10) was measured in all the subjects at the start of the treatment and at a follow up of two months. Mean age of the study subjects was 40.96 years. Mean duration of symptoms at presentation was 1 month and 17 days. The induration on Tuberculin skin test (TST) was between 10-20mm in most (62.5%) of the study subjects. Majority (45%) showed moderately advanced disease on chest x-ray. There was no association of IP-10 with TST diameter and gene x-pert. Similarly, no significant difference in IP-10 levels was found in relation to sputum grading and x-ray score at diagnosis and after 2 months of treatment. IP-10 has very limited role in diagnosis of active TB in especially in high TB burden countries. The role of IP-10 in follow up of PTB patients could not be ascertained by our study. However, more studies are needed in this pretext with larger sample size and extended duration of follow up.
World Health Organization. Global tuberculosis report 2020. Available from: https://www.who.int/publications/i/item/9789240013131
Khusro A, Aarti C, Salem AZM. An overview on the current status of tuberculosis and its biomarkers. J Biol Chemistry 2000;275:28326-31.
Nguyen TNA, Anton-Le Berre V, Bañuls A-L, Nguyen TVA. Molecular diagnosis of drug-resistant tuberculosis; A literature review. Front Microbiol 2019;10:794.
DOI: https://doi.org/10.3389/fmicb.2019.00794
El-emiry FA, Attia GA, Ahmad AY, Sakr BM. Diagnostic value of inducible protein-10 in pulmonary tuberculosis. Egypt J Chest Dis Tubercul 2016;65:219-25.
DOI: https://doi.org/10.1016/j.ejcdt.2015.08.012
Hong JY, Jung GS, Kim H, Kim YM, Lee HJ, Cho S-N, et al. Efficacy of inducible protein 10 as a biomarker for the diagnosis of tuberculosis. Int J Infect Dis 2012;16:e855-9.
DOI: https://doi.org/10.1016/j.ijid.2012.07.013
Kabeer BSA, Raman B, Thomas A, et al.Role of QuantiFERON-TB gold, interferon gamma inducible protein-10 and tuberculin skin test in active tuberculosis diagnosis. PLoS One 2010;5:e9051.
DOI: https://doi.org/10.1371/journal.pone.0009051
Central TB Division, Directorate General of Health Services, Ministry of Health with Family Welfare. National strategic plan for tuberculosis elimination 2017-2025. Accessed: 2020 Jul 15. Available from: https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf
World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Available from: http://www.who.int/tb/publications/use-of-lf-lam-tb-hiv/en/
Ruhwald M, Aabye MG, Ravn P. IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions. Expert Rev Mol Diagn 2012;12:175-87.
DOI: https://doi.org/10.1586/erm.11.97
Dufour JH, Dziejman M, Liu MT, et al. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002;168:3195-204.
DOI: https://doi.org/10.4049/jimmunol.168.7.3195
Lee J, Lee J-Y, Choi H-H, et al. Elevated levels of interferon-inducible protein10 (IP)-10/CXCL10, but not of interferon-γ, in patients with pulmonary tuberculosis. J Bacteriol Virol 2007;37:137-46.
DOI: https://doi.org/10.4167/jbv.2007.37.3.137
Qiu X, Tang Y, Yue Y, et al. Accuracy of interferon-γ-induced protein 10 for diagnosing latent tuberculosis infection: a systematic review and meta-analysis. Clin Microbiol Infect 2019;25:667–72.
DOI: https://doi.org/10.1016/j.cmi.2018.12.006
Qiu X, Xiong T, Su X, et al. Accumulate evidence for IP-10 in diagnosing pulmonary tuberculosis. BMC Infect Dis 2019;19:924.
DOI: https://doi.org/10.1186/s12879-019-4466-5
Qiu X, Tang Y, Zou R, et al. Diagnostic accuracy of interferon-gamma-induced protein 10 for differentiating active tuberculosis from latent tuberculosis: A meta-analysis. Sci Rep 2019;9:11408.
DOI: https://doi.org/10.1038/s41598-019-47923-w
Aabye MG, Ruhwald M, Praygod G, et al. Potential of interferon-γ-inducible protein 10 in improving tuberculosis diagnosis in HIV-infected patients. Eur Respir J 2010;36:1488–90.
DOI: https://doi.org/10.1183/09031936.00039010
Petrone L, Cannas A, Aloi F, Nsubuga M, Sserumkuma J, Nazziwa RA, et al. Blood or urine IP-10 cannot discriminate between active tuberculosis and respiratory diseases different from tuberculosis in children. Biomed Res Int 2015;2015:589471.
DOI: https://doi.org/10.1155/2015/589471
Whittaker E, Gordon A, Kampmann B. Is IP-10 a better biomarker for active and latent tuberculosis in children than IFNgamma? PLoS One 2008;3:e3901.
DOI: https://doi.org/10.1371/journal.pone.0003901
Tonby K, Ruhwald M, Kvale D, Dyrhol-Riise AM. IP-10 measured by dry plasma spots as biomarker for therapy responses in Mycobacterium tuberculosis infection. Sci Rep 2015;5:9223.
DOI: https://doi.org/10.1038/srep09223
Azzurri A, Sow OY, Amedei A, et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 2005;7:1–8.
DOI: https://doi.org/10.1016/j.micinf.2004.09.004
Wergeland I, Pullar N, Assmus J, et al. IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy. J Infect 2015;70:381-91.
DOI: https://doi.org/10.1016/j.jinf.2014.12.019
Kobashi Y, MouriK, Kato S, Oka M. Clinical evaluation of IP-10 and MIG for the diagnosis of active tuberculosis disease. Mycobact Dis 2015;5:1000185.
DOI: https://doi.org/10.4172/2161-1068.1000185
Jeong YH, Hur Y-G, Lee H, et al. Discrimination between active and latent tuberculosis based on ratio of antigen-specific to mitogen-induced IP-10 production. J Clin Microbiol 2015;53:504–10.
DOI: https://doi.org/10.1128/JCM.02758-14
How to Cite
Saini, Himanshu, Parul Mrigpuri, Balakrishnan Menon, and Sonal Sonal. 2022. “Role of IP-10 During Follow up of Pulmonary Tuberculosis Patients”. Monaldi Archives for Chest Disease 92 (4). https://doi.org/10.4081/monaldi.2022.2022.
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Devika Tayal, Prerna Jain, Mamta Bhardwaj, Amit Sharma, Diabetes mellitus in acute exacerbation of chronic obstructive pulmonary disease – the tip of the iceberg , Monaldi Archives for Chest Disease: Early Access
- Miguel Osejo-Betancourt, Sebastian Molina-Paez , Mariana Rubio-Romero , Pulmonary tuberculosis and COVID-19 coinfection: A new medical challenge , Monaldi Archives for Chest Disease: Vol. 92 No. 3 (2022)
- Nitesh Gupta, A J Mahendran, Shibdas Chakrabarti, Sumita Agrawal, Microscopic polyangiitis in a case of silica exposure: a rare presentation , Monaldi Archives for Chest Disease: Vol. 89 No. 3 (2019)
- Vijay Noel Nongpiur, Saurabh Mittal, Karan Madan, Anant Mohan, Vijay Hadda, Utilization of endobronchial electrocautery for removal of an impacted airway foreign body , Monaldi Archives for Chest Disease: Vol. 90 No. 3 (2020)
- Cuneyt Tetikkurt, Nurbanu Inci, Hail Yanardag, Diagnostic utility of PET/CT in a patient with miliary tuberculosis , Monaldi Archives for Chest Disease: Vol. 89 No. 2 (2019)
- E. Radzikowska, J. Pawlowski, M. Chabowski, R. Langfort, Constrictive bronchiolitis obliterans in patient with Castelman's disease , Monaldi Archives for Chest Disease: Vol. 63 No. 4 (2005): Pulmonary series
- Yuvarajan Sivagnaname, Praveen Radhakrishnan, Antonius Maria Selvam, Malignant bronchial ulcer with coexistent pulmonary tuberculosis , Monaldi Archives for Chest Disease: Vol. 89 No. 3 (2019)
- Saulius Diktanas, Oleksandr Korotych, Yuliia Sereda, Ogtay Gozalov, Olga Rubcova, Jay Achar, Factors associated with time to sputum culture conversion of rifampicin-resistant tuberculosis patients in Klaipeda, Lithuania in 2016-2019: a cohort study , Monaldi Archives for Chest Disease: Vol. 91 No. 1 (2021)
- Muniza Bai, Vishnukanth Govindaraj, Abhishek Singh Chauhan, Bheemanati Hanuman Srinivas, Jinkala Sree Rekha, Vijayarangam Narenchandra, Metastatic malignant peripheral nerve sheath tumor. A diagnostic surprise , Monaldi Archives for Chest Disease: Vol. 91 No. 2 (2021)
- Manoj Kumar, Rajesh Kumar Gupta, Raj Kumar, Sonam Spalgais, Anil Kumar Mavi, Kamal Singh, Cockroach exposure and its allergy sensitization in asthma patients , Monaldi Archives for Chest Disease: Vol. 91 No. 3 (2021)
<< < 22 23 24 25 26 27 28 29 30 31 > >>
You may also start an advanced similarity search for this article.
